Logomix is a pioneering synthetic biology company. With its unprecedented genome engineering platform, Geno-Writing™, Logomix facilitates precise and Mb-scale manipulation of genomic sequences within human cells, leads the development of super-functionalized hypoimmune cells to address critical limitations in contemporary cell therapy approaches,